ZNTL earnings analysis
What we found in ZNTL's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Zentalis Pharmaceuticals reported its Q1 2026 results with a net loss of $35.4 million, resulting in an EPS of -$0.49, a slight beat on estimates of -$0.53. Revenue remains undisclosed, but cash reserves stand at $211.8 million, expected to fund operations into late 2027. The company faces ongoing challenges as clinical trials for its lead product, azenosertib, progress, amidst regulatory and competitive pressures.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Narrow EPS Loss Compared to Estimates
- Diluted EPS was reported at -$0.49, better than the estimated -$0.53.
- Strong Cash Position
- Zentalis ended the quarter with $211.8 million in cash, expected to last into late 2027.
- Decreased Operating Expenses
- Total operating expenses fell significantly to $37.9 million from $45.6 million a year ago, mainly due to restructuring efforts.
- Improved Clinical Trial Focus
- Management emphasizes progress in DENALI and ASPENOVA trials for azenosertib as key drivers for future success.
- No Revenue Generation
- The company has not generated any revenue from product sales to date, continuing to rely on funding for operations.
- Ongoing Regulatory Hurdles
- Management expressed caution regarding the regulatory landscape affecting future commercialization efforts.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Dependence on azenosertib
- The company is heavily reliant on the success of azenosertib, which may face execution risks.
- Significant Operating Losses
- Zentalis reported a net loss of $35.4 million in Q1 2026, increasing operational financial strain.
- Patent and Intellectual Property Risks
- Litigation or challenges to Zentalis' intellectual property could adversely affect its product development capabilities.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.49
What they said about what is next.
Management expects cash reserves to support operations into late 2027.
The filing reads about the same as the one before it.
What came before.
- 10-K · March 26, 2026
- Zentalis is a clinical‑stage oncology company focused on azenosertib (ZN‑c3), a WEE1 inhibitor prioritized toward registration in Cyclin E1‑positive platinum‑resistant ovarian cancer (PROC). The 10‑K highlights strong…
- 10-Q · August 6, 2025
- Zentalis reported no revenue for the three months ended June 30, 2025 and delivered an improved net loss per share of $(0.37) versus $(1.24) in Q2 2024, driven by materially lower operating expenses and a positive swing…
- 10-K · March 26, 2025
- Zentalis is a clinical‑stage biotech focused on azenosertib (ZN-c3), a WEE1 inhibitor, and is prioritizing rapid development in Cyclin E1+ platinum‑resistant ovarian cancer (PROC). The company reported meaningful…
- 10-Q · November 12, 2024
- Zentalis reported a third-quarter net loss of $40,158,000 (GAAP diluted loss per share $0.56) with no license revenue in the quarter. Net loss and EPS improved versus the year‑ago quarter (Q3 2023 net loss $55,540,000;…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing ZNTL makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever